发布时间:
2021
-
03
-
17
点击次数:
0
所属职位：
总经理，共同创始人
所属公司：
亚盛医药
个人简介：
Dr. Guo has been working in the healthcare industry since 1991, including Pfizer, Ascenta Therapeutics, and Ascentage Pharma. At Pfizer (1995-2005) with various technical and management roles, Dr. Guo participated in many NCE drug R&D projects, several of which have successfully reached commercial stages. At Ascenta (2005-2009), Dr. Guo was the founding Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which is likely the first company engaged in global NCE drug R&D in China from 2005. Dr. Guo played an important role in Ascenta’s $600M global out-licensing deals (i.e., with Sanofi-Aventis in 2010 and with Debio in 2011). Based on Ascenta (Shanghai) team, Dr. Guo co-founded Ascentage Pharma in September 2009, a globally positioned China innovative NCE drug R&D company, and currently serves as President & COO. The company has quickly built up a pipeline of 8 clinical-stage NCE projects along with several IND-enabling and discovery stage projects, covering oncology and anti-viral / anti-aging therapeutic areas through its apoptosis/PPI platform. Ascentage Pharma had a successful IPO at Hong Kong Stock Exchange in 2019. During 2002-2005, Dr. Guo served as an Overseas Advisor for Beijing Zhongguangcun Biotech Park in China. He has been an adjunct professor, a faculty and graduate student adviser for the IPEM program at Peking University during 2007-2018. Dr. Guo served as an Independent Board Director at Porton Corporation (Chongqing, China) during 2012-2016, overseeing its successful IPO at Shengzhen Exchange, China, in 2014. As a co-founder and the founding Chairman, Dr. Guo has served on Board of Directors of SABPA (www.sabpa.org). Dr. Guo received his Ph.D. degree in Organic Chemistry at the University of California at San Diego; M.Sc. in Medicinal Chemistry at Institute of Materia Medica, Chinese Academy of Sciences; and B.S. in Chemistry at Peking Normal University.